OPTH

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) --  Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest production batch of its MDMA (3,4-methylenedioxymethamphetamine) finished drug product. The capsules were manufactured at Optimi's GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed Phase 3 clinical trial of MDMA-assisted therapy in Canada (the “Proposed Phase 3 Trial”) for the treatment of post-traumatic stress disorder ("PTSD"), its next commercial export to Australia planned before the end of 2026, and a previously announced clinical trial in Israel in partnership with the Multidisciplinary Association for Psychedelic Studies ("MAPS").

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company's cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence.

VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D.

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C.

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.

Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.